SCHEMBL5659537

SCHEMBL5659537

Cc1cccc(N2C(=O)[C@](c3cc(C)c(O)c(C)c3)(c3ccc(O)c(C)c3O)c3ccccc32)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.36
HSP90AA1 P07900 1/20 0.35
MGLL Q99685 1/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
LMNA P02545 3/20 0.35
L3MBTL1 Q9Y468 4/20 0.34
NPSR1 Q6W5P4 2/20 0.34
MAPT P10636 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
XBP1 P17861 1/20 0.34
HSD17B10 Q99714 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
TP53 P04637 1/20 0.32
CNR1 P21554 2/20 0.32
GPR55 Q9Y2T6 2/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14457635 1.00 SLC6A2 (0.36) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5663116 1.00 SLC6A2 (0.36) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5659702 0.93 NPSR1 (0.37) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5659320 0.90 CNR1 (0.37) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5661875 0.90 SLC6A2 (0.37) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5662233 0.89 HSP90AA1 (0.41) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5658788 0.89 MAPT (0.38) MGLLMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5661607 0.86 OPRL1 (0.33)
SCHEMBL5660824 0.84 SLC6A2 (0.35) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5658939 0.84 SLC6A2 (0.36) SLC6A2HSP90AA1MGLLCACNA1BAPBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed
EP-1487792-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003078394-A1 DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 SLC6A2 1300/4885HSP90AA1 351/4885MGLL 3012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.